학술논문
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study
Document Type
Article
Author
Jackson, D.J.; Heaney, L.G.; Humbert, M.; Kent, B.D.; Shavit, A.; Menzies-Gow, A.; Olinger, L.; Hiljemark, L.; Cohen, D.; Korn, S.; Kroegel, C.; Caruso, C.; Baglivo, I.; Colantuono, S.; Jackson, D.; Skowasch, D.; Di Marco, F.; Couturaud, F.; Käßner, F.; Cwiek, I.; Teber, M.; Knetsch, K.; Preuß, J.; Devouassoux, G.; Milger-Kneidinger, K.; Heaney, L.; Jerrentrup, L.; Jandl, M.; Timmermann, H.; Probst, B.; D'Amato, M.; Hoffmann, M.; Bonniaud, P.; Beltramo, G.; Girodet, P.-O.; Berger, P.; Nasser, S.; Fry, S.; Aries, S.P.; Koehler, T.; Harrison, T.
Source
In: The Lancet . (The Lancet, 20 January 2024, 403(10423):271-281)
Subject
Language
English
ISSN
1474547X
01406736
01406736